Project description
Secretome profiling as a marker of drug efficacy
Medications can alter the secretome by influencing the types and amounts of proteins that cells release, reflecting changes in cellular metabolism, immune response or stress. These drug-induced changes in secreted proteins can provide important insights into the drug's efficacy, toxicity or potential to induce resistance, serving as early biomarkers for treatment outcomes. The ERC-funded THRON-SEC project aims to validate the technical and commercial feasibility of secretome profiling as a tool for assessing drug efficacy and safety. The study is based on a novel technique called THRONCAT that enables the identification and quantification of secreted proteins containing chemically modified analogues of the amino acid threonine.
Objective
Under normal conditions, cells release proteins (secretome) to regulate fundamental processes like metabolism and immunity. Many diseases and their corresponding treatments involve alterations in the secretome and the cellular microenvironment. Understanding drug-induced changes in the secretome is vital for early assessment of drug efficacy, toxicity, and resistance development. We have developed a metabolic protein labeling technique based on bioorthogonal threonine analogues, THRONCAT, that offers sensitive and non-perturbing analysis of drug-induced changes in the cellular secretome. THRONCAT enables the identification and quantification of secreted proteins in response to drug treatment, even in sensitive cellular systems. We envision that Drug-Induced Secretome Profiling (DISP), holds promise for improving clinical and preclinical drug development by detecting specific signaling proteins and biomarkers early in the development process and validated secreted proteins may serve as biomarkers to assess treatment efficacy during drug development and clinical trials. In this proof of concept proposal we will validate the technical and commercial feasibility of a platform that allows the analysis of the cellular secretome upon drug treatment. THRON-SEC will: 1) Show that secretome profiling upon drug treatment allows the elucidation of a drugs efficacy and mechanism of action as well as early detection of toxicity and resistance markers; and 2) Perform IPR, market and business case analyses to ensure commercial feasibility and entry to market.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2024-POC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2311 EZ Leiden
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.